Genesis San Diego Secures Excellos, Marking Downtown San Diego’s Second-Ever Life Sciences Lab Lease
CHARLOTTE, N.C. and SAN DIEGO, Oct. 26, 2022 /PRNewswire/ — Barings, one of the world’s largest diversified real estate investment managers, along with Phase 3 Real Estate Partners and Bain Capital Real Estate, announced today that their joint venture has secured Excellos as a tenant at Genesis San Diego, a premier Class A life science […]
Single-Cell Immune Profiling Reveals Remarkable Changes Associated with COVID-19
Researchers at the La Jolla Institute for Immunology cite using Excellos sourced healthy donor starting material to carry out single-cell immune profiling for their research on severe COVID-19. [1] Great strides have been made in fighting the SARS-CoV-2 virus, the most noteworthy being the development and distribution of the COVID-19 vaccine. However, we must keep […]
Trogocytosis – A Case of T cell Identity Theft Offers Essential Clue to Solving MS
A case of immune T cell identity theft (trogocytosis) gave German scientists the vital clue they needed to understand a key mechanism behind the development of multiple sclerosis (MS). In a recently published paper, scientists at the Institute of Neuropathology in Gottingen, Germany, describe new research that could help doctors treat MS. [1] The key […]
Efficient Isolation of Antigen-Specific B Cells
Scientists at Scripps Research Center in La Jolla are working to streamline monoclonal antibody vaccine development by devising more efficient ways to screen for rare B antigen-specific B cells. [1] Today, monoclonal antibodies (mAbs) are at the forefront of vaccine research as scientists continue to develop new treatments to fight cancer, autoimmunity, and infectious disease. […]
Cancer Immunotherapy – High Precision & Remote-Controlled
Researchers at UCSD and Memorial Sloan Kettering Cancer Center used Excellos healthy donor starting material to carry out a fascinating study on ultrasonic activation of cancer immunotherapy. CAR-T cell therapy is a paradigm shifting therapeutic with the potential to have an immense impact on cancer treatment options. The number of CAR-T therapies in clinical trial […]
NK cell therapy – Excellos Cells Aid Discovery of Key Cancer Killing Target
NK cell therapy holds the promise of new therapeutics for underserved cancer indications. A recent publication in Nature Communications uses Excellos sourced cellular starting materials for research on the mechanisms behind NK cell cytotoxicity. [1] The capacity for cancer cells to avoid immune detection is notorious. Normally, cells that are faulty, diseased, or reaching the […]
Allogeneic CAR-T Study – Healthy Donor Cells Outperform Patient Cells in Cancer Therapy
A new Allogeneic CAR-T study has shown CAR-T cells derived from healthy donors to be superior at fighting cancer compared to CAR-T cells derived from patients. [1] In a press release, biotechnology company Allogene Therapeutics announced preclinical results from their study on the treatment of multiple myeloma using allogeneic CAR-T cell therapy. Multiple myeloma is […]
Effective Solutions to Cell Therapy Supply Chain & Logistics
Where the Cell Therapy industry is facing an ever-growing complexity in supply chain and logistics, now is the time to optimize the cell therapy supply chain to create a dependable supply of cellular therapeutics. Adam Clark, Director of Commercial Operations here at Excellos recently attended the Supply Chain & Logistics for Cell Therapies Summit in […]
Cell Therapies – Building Solid Foundations for Success
Raw material experts Dr. David Wellis and Dr. Robert Tressler want to share their knowledge on how to select and source cellular starting materials that build the foundations of successful cell therapies. Dr. Wellis and Dr. Tressler are life sciences experts; both boast decades of experience at the forefront of biomedical research and technology. Mere […]
Part 2: Donor Immune Cell Characterization and Successful Cell Therapy
Next-level donor immune cell characterization can be used as a foundation for promoting high patient response rates. Last week in Part 1 of our donor characterization series, we dove into T cell function and donor immune cell characterization, and how those factors affect how well a patient may respond to immunotherapy. In Part 2 of […]